Biomarkers in acute kidney injury.
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
15 Sep 2024
15 Sep 2024
Historique:
received:
14
06
2024
accepted:
07
08
2024
medline:
16
9
2024
pubmed:
16
9
2024
entrez:
15
9
2024
Statut:
epublish
Résumé
Acute kidney injury (AKI) is a multifactorial syndrome with a high risk of short- and long-term complications as well as increased health care costs. The traditional biomarkers of AKI, serum creatinine and urine output, have important limitations. The discovery of new functional and damage/stress biomarkers has enabled a more precise delineation of the aetiology, pathophysiology, site, mechanisms, and severity of injury. This has allowed earlier diagnosis, better prognostication, and the identification of AKI sub-phenotypes. In this review, we summarize the roles and challenges of these new biomarkers in clinical practice and research.
Identifiants
pubmed: 39279017
doi: 10.1186/s13613-024-01360-9
pii: 10.1186/s13613-024-01360-9
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
145Informations de copyright
© 2024. The Author(s).
Références
Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet. 2019;394(10212):1949–64.
pubmed: 31777389
doi: 10.1016/S0140-6736(19)32563-2
Pickkers P, Darmon M, Hoste E, Joannidis M, Legrand M, Ostermann M, et al. Acute kidney injury in the critically ill: an updated review on pathophysiology and management. Intensive Care Med. 2021;47(8):835–50.
pubmed: 34213593
pmcid: 8249842
doi: 10.1007/s00134-021-06454-7
Haines RW, Powell-Tuck J, Leonard H, Crichton S, Ostermann M. Long-term kidney function of patients discharged from hospital after an intensive care admission: observational cohort study. Sci Rep. 2021;11(1):9928.
pubmed: 33976354
pmcid: 8113423
doi: 10.1038/s41598-021-89454-3
Ostermann M, Lumlertgul N, James MT. Dialysis-Dependent acute kidney injury-a risk factor for adverse outcomes. Jama Netw Open. 2024;7(3): e240346.
pubmed: 38457185
doi: 10.1001/jamanetworkopen.2024.0346
McNicholas BA, Haines R, Ostermann M. Survive or thrive after ICU: what’s the score? Ann Intensive Care. 2023;13(1):43.
pubmed: 37202549
pmcid: 10195929
doi: 10.1186/s13613-023-01140-x
McNicholas B, Akcan Arikan A, Ostermann M. Quality of life after acute kidney injury. Curr Opin Crit Care. 2023;29(6):566–79.
pubmed: 37861184
doi: 10.1097/MCC.0000000000001090
Ostermann M, Basu RK, Mehta RL. Acute kidney injury. Intensive Care Med. 2023;49(2):219–22.
pubmed: 36592201
doi: 10.1007/s00134-022-06946-0
Lumlertgul N, Baker E, Pearson E, Dalrymple KV, Pan J, Jheeta A, et al. Changing epidemiology of acute kidney injury in critically ill patients with COVID-19: a prospective cohort. Ann Intensive Care. 2022;12(1):118.
pubmed: 36575315
pmcid: 9794481
doi: 10.1186/s13613-022-01094-6
Kellum JA, Lameire N. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17(1):204.
pubmed: 23394211
pmcid: 4057151
doi: 10.1186/cc11454
Kashani K, Rosner MH, Ostermann M. Creatinine: from physiology to clinical application. Eur J Intern Med. 2020;72:9–14.
pubmed: 31708357
doi: 10.1016/j.ejim.2019.10.025
Liu KD, Thompson BT, Ancukiewicz M, Steingrub JS, Douglas IS, Matthay MA, et al. Acute kidney injury in patients with acute lung injury: impact of fluid accumulation on classification of acute kidney injury and associated outcomes. Crit Care Med. 2011;39(12):2665–71.
pubmed: 21785346
pmcid: 3220741
doi: 10.1097/CCM.0b013e318228234b
Ostermann M, Joannidis M. Acute kidney injury 2016: diagnosis and diagnostic workup. Crit Care. 2016;20(1):299.
pubmed: 27670788
pmcid: 5037640
doi: 10.1186/s13054-016-1478-z
Ostermann M, Shaw AD, Joannidis M. Management of oliguria. Intensive Care Med. 2023;49(1):103–6.
pubmed: 36266588
doi: 10.1007/s00134-022-06909-5
Ostermann M, Awdishu L, Legrand M. Using diuretic therapy in the critically ill patient. Intensive Care Med. 2024. https://doi.org/10.1007/s00134-024-07441-4 .
doi: 10.1007/s00134-024-07441-4
pubmed: 39133282
pmcid: 11377501
Törnblom S, Nisula S, Petäjä L, Vaara ST, Haapio M, Pesonen E, et al. Urine NGAL as a biomarker for septic AKI: a critical appraisal of clinical utility—data from the observational FINNAKI study. Ann Intensive Care. 2020;10(1):51.
pubmed: 32347418
pmcid: 7188747
doi: 10.1186/s13613-020-00667-7
Emlet DR, Pastor-Soler N, Marciszyn A, Wen X, Gomez H, Humphries W, et al. Insulin-like growth factor binding protein 7 and tissue inhibitor of metalloproteinases-2: differential expression and secretion in human kidney tubule cells. Am J Physiol Renal Physiol. 2017;312(2):F284–96.
pubmed: 28003188
doi: 10.1152/ajprenal.00271.2016
McCullough PA, Ostermann M, Forni LG, Bihorac A, Koyner JL, Chawla LS, et al. Serial urinary tissue inhibitor of metalloproteinase-2 and insulin-like growth factor-binding protein 7 and the prognosis for acute kidney injury over the course of critical illness. Cardiorenal Med. 2019;9(6):358–69.
pubmed: 31618746
doi: 10.1159/000502837
Laing KJ, Secombes CJ. Chemokines. Dev Comp Immunol. 2004;28(5):443–60.
pubmed: 15062643
doi: 10.1016/j.dci.2003.09.006
Hoste E, Bihorac A, Al-Khafaji A, Ortega LM, Ostermann M, Haase M, et al. Identification and validation of biomarkers of persistent acute kidney injury: the RUBY study. Intensive Care Med. 2020;46(5):943–53.
pubmed: 32025755
pmcid: 7210248
doi: 10.1007/s00134-019-05919-0
Moledina DG, Wilson FP, Pober JS, Perazella MA, Singh N, Luciano RL, et al. Urine TNF-α and IL-9 for clinical diagnosis of acute interstitial nephritis. JCI Insight. 2019. https://doi.org/10.1172/jci.insight.127456 .
doi: 10.1172/jci.insight.127456
pubmed: 31092735
pmcid: 6542610
Ostermann M, Karsten E, Lumlertgul N. Biomarker-based management of AKI: fact or fantasy? Nephron. 2022;146(3):295–301.
pubmed: 34515152
doi: 10.1159/000518365
Kane-Gill SL, Meersch M, Bell M. Biomarker-guided management of acute kidney injury. Curr Opin Crit Care. 2020;26(6):556–62.
pubmed: 33027146
doi: 10.1097/MCC.0000000000000777
Honore PM, Jacobs R, Joannes-Boyau O, Verfaillie L, De Regt J, Van Gorp V, et al. Biomarkers for early diagnosis of AKI in the ICU: ready for prime time use at the bedside? Ann Intensive Care. 2012;2(1):24.
pubmed: 22747706
pmcid: 3475083
doi: 10.1186/2110-5820-2-24
Jia H-M, Cheng L, Weng Y-B, Wang J-Y, Zheng X, Jiang Y-J, et al. Cell cycle arrest biomarkers for predicting renal recovery from acute kidney injury: a prospective validation study. Ann Intensive Care. 2022;12(1):14.
pubmed: 35150348
pmcid: 8840946
doi: 10.1186/s13613-022-00989-8
Fuhrman DY, Stanski NL, Krawczeski CD, Greenberg JH, Arikan AAA, Basu RK, et al. A proposed framework for advancing acute kidney injury risk stratification and diagnosis in children: a report from the 26th acute disease quality initiative (ADQI) conference. Pediatr Nephrol. 2024;39(3):929–39.
pubmed: 37670082
doi: 10.1007/s00467-023-06133-3
Meersch M, Schmidt C, Hoffmeier A, Van Aken H, Wempe C, Gerss J, et al. Prevention of cardiac surgery-associated AKI by implementing the KDIGO guidelines in high risk patients identified by biomarkers: the PrevAKI randomized controlled trial. Intensive Care Med. 2017;43(11):1551–61.
pubmed: 28110412
pmcid: 5633630
doi: 10.1007/s00134-016-4670-3
Göcze I, Jauch D, Götz M, Kennedy P, Jung B, Zeman F, et al. Biomarker-guided intervention to prevent acute kidney injury after major surgery: the prospective randomized BigpAK study. Ann Surg. 2018;267(6):1013–20.
pubmed: 28857811
doi: 10.1097/SLA.0000000000002485
Zarbock A, Küllmar M, Ostermann M, Lucchese G, Baig K, Cennamo A, et al. Prevention of cardiac surgery-associated acute kidney injury by Implementing the KDIGO guidelines in High-risk patients identified by biomarkers: the prevAKI-Multicenter randomized controlled trial. Anesth Analg. 2021;133(2):292–302.
pubmed: 33684086
doi: 10.1213/ANE.0000000000005458
Stanski N, Menon S, Goldstein SL, Basu RK. Integration of urinary neutrophil gelatinase-associated lipocalin with serum creatinine delineates acute kidney injury phenotypes in critically ill children. J Crit Care. 2019;53:1–7.
pubmed: 31174170
doi: 10.1016/j.jcrc.2019.05.017
Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 2009;54(6):1012–24.
pubmed: 19850388
doi: 10.1053/j.ajkd.2009.07.020
Ho J, Tangri N, Komenda P, Kaushal A, Sood M, Brar R, et al. Urinary, plasma, and serum biomarkers’ utility for predicting acute kidney injury associated with cardiac surgery in adults: a meta-analysis. Am J Kidney Dis. 2015;66(6):993–1005.
pubmed: 26253993
doi: 10.1053/j.ajkd.2015.06.018
Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw SM, Bell M, et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013;17(1):R25.
pubmed: 23388612
pmcid: 4057242
doi: 10.1186/cc12503
Forni LG, Joannidis M, Artigas A, Bell M, Hoste E, Joannes-Boyau O, et al. Characterising acute kidney injury: the complementary roles of biomarkers of renal stress and renal function. J Crit Care. 2022;71: 154066.
pubmed: 35696851
doi: 10.1016/j.jcrc.2022.154066
Huang F, Zeng Y, Lv L, Chen Y, Yan Y, Luo L, et al. Predictive value of urinary cell cycle arrest biomarkers for all cause-acute kidney injury: a meta-analysis. Sci Rep. 2023;13(1):6037.
pubmed: 37055509
pmcid: 10102152
doi: 10.1038/s41598-023-33233-9
Lin LC, Chuan MH, Liu JH, Liao HW, Ng LL, Magnusson M, et al. Proenkephalin as a biomarker correlates with acute kidney injury: a systematic review with meta-analysis and trial sequential analysis. Crit Care. 2023;27(1):481.
pubmed: 38057904
pmcid: 10702091
doi: 10.1186/s13054-023-04747-5
Ahmad T, Jackson K, Rao VS, Tang WHW, Brisco-Bacik MA, Chen HH, et al. Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury. Circulation. 2018;137(19):2016–28.
pubmed: 29352071
pmcid: 6066176
doi: 10.1161/CIRCULATIONAHA.117.030112
Ostermann M, McCullough PA, Forni LG, Bagshaw SM, Joannidis M, Shi J, et al. Kinetics of urinary cell cycle arrest markers for acute kidney injury following exposure to potential renal insults. Crit Care Med. 2018;46(3):375–83.
pubmed: 29189343
pmcid: 5821475
doi: 10.1097/CCM.0000000000002847
Fudim M, Loungani R, Doerfler SM, Coles A, Greene SJ, Cooper LB, et al. Worsening renal function during decongestion among patients hospitalized for heart failure: findings from the evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness (ESCAPE) trial. Am Heart J. 2018;204:163–73.
pubmed: 30121018
doi: 10.1016/j.ahj.2018.07.019
Nadim MK, Kellum JA, Forni L, Francoz C, Asrani SK, Ostermann M, et al. Acute kidney injury in patients with cirrhosis: acute disease quality initiative (ADQI) and international club of ascites (ICA) joint multidisciplinary consensus meeting. J Hepatol. 2024. https://doi.org/10.1016/j.jhep.2024.03.031 .
doi: 10.1016/j.jhep.2024.03.031
pubmed: 38527522
pmcid: 11193657
Nadim MK, Forni LG, Ostermann M. Hepatorenal syndrome in the intensive care unit. Intensive Care Med. 2024;50(6):978–81.
pubmed: 38695933
doi: 10.1007/s00134-024-07438-z
Gambino C, Piano S, Stenico M, Tonon M, Brocca A, Calvino V, et al. Diagnostic and prognostic performance of urinary neutrophil gelatinase-associated lipocalin in patients with cirrhosis and acute kidney injury. Hepatology. 2023;77(5):1630–8.
pubmed: 36125403
Kane-Gill SL, Ostermann M, Shi J, Joyce EL, Kellum JA. Evaluating renal stress using pharmacokinetic urinary biomarker data in critically ill patients receiving vancomycin and/or piperacillin-Tazobactam: a secondary analysis of the multicenter sapphire study. Drug Saf. 2019;42(10):1149–55.
pubmed: 31240688
doi: 10.1007/s40264-019-00846-x
Moledina DG, Wilson FP, Kukova L, Obeid W, Luciano R, Kuperman M, et al. Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis. Nephrol Dial Transplant. 2021;36(10):1851–8.
pubmed: 33125471
doi: 10.1093/ndt/gfaa169
Chawla LS, Bellomo R, Bihorac A, Goldstein SL, Siew ED, Bagshaw SM, et al. Acute kidney disease and renal recovery: consensus report of the acute disease quality initiative (ADQI) 16 workgroup. Nat Rev Nephrol. 2017;13(4):241–57.
pubmed: 28239173
doi: 10.1038/nrneph.2017.2
Forni LG, Darmon M, Ostermann M, Oudemans-van Straaten HM, Pettilä V, Prowle JR, et al. Renal recovery after acute kidney injury. Intensive Care Med. 2017;43(6):855–66.
pubmed: 28466146
pmcid: 5487594
doi: 10.1007/s00134-017-4809-x
Chen YT, Pan HC, Hsu CK, Sun CY, Chen CY, Chen YH, et al. Performance of urinary C-C motif chemokine ligand 14 for the prediction of persistent acute kidney injury: a systematic review and meta-analysis. Crit Care. 2023;27(1):318.
pubmed: 37596698
pmcid: 10439656
doi: 10.1186/s13054-023-04610-7
Kellum JA, Bagshaw SM, Demirjian S, Forni L, Joannidis M, Kampf JP, et al. CCL14 testing to guide clinical practice in patients with AKI: results from an international expert panel. J Crit Care. 2024;82: 154816.
pubmed: 38678981
doi: 10.1016/j.jcrc.2024.154816
Hollinger A, Wittebole X, François B, Pickkers P, Antonelli M, Gayat E, et al. Proenkephalin A 119–159 (Penkid) is an early biomarker of septic acute kidney injury: the kidney in sepsis and septic shock (Kid-SSS) study. Kidney Int Rep. 2018;3(6):1424–33.
pubmed: 30450469
pmcid: 6224621
doi: 10.1016/j.ekir.2018.08.006
Schunk SJ, Zarbock A, Meersch M, Küllmar M, Kellum JA, Schmit D, et al. Association between urinary dickkopf-3, acute kidney injury, and subsequent loss of kidney function in patients undergoing cardiac surgery: an observational cohort study. Lancet. 2019;394(10197):488–96.
pubmed: 31202596
doi: 10.1016/S0140-6736(19)30769-X
Molinari L, Del Rio-Pertuz G, Smith A, Landsittel DP, Singbartl K, Palevsky PM, et al. Utility of biomarkers for sepsis-associated acute kidney injury staging. JAMA Netw Open. 2022;5(5): e2212709.
pubmed: 35583867
pmcid: 9118077
doi: 10.1001/jamanetworkopen.2022.12709
Klein SJ, Brandtner AK, Lehner GF, Ulmer H, Bagshaw SM, Wiedermann CJ, et al. Biomarkers for prediction of renal replacement therapy in acute kidney injury: a systematic review and meta-analysis. Intensive Care Med. 2018;44(3):323–36.
pubmed: 29541790
pmcid: 5861176
doi: 10.1007/s00134-018-5126-8
Ostermann M, Dickie H, Barrett NA. Renal replacement therapy in critically ill patients with acute kidney injury–when to start. Nephrol Dial Transplant. 2012;27(6):2242–8.
pubmed: 22231034
doi: 10.1093/ndt/gfr707
Ostermann M, Bagshaw SM, Lumlertgul N, Wald R. Indications for and timing of initiation of KRT. Clin J Am Soc Nephrol. 2023;18(1):113–20.
pubmed: 36100262
Ostermann M, Joannidis M, Pani A, Floris M, De Rosa S, Kellum JA, et al. Patient selection and timing of continuous renal replacement therapy. Blood Purif. 2016;42(3):224–37.
pubmed: 27561956
doi: 10.1159/000448506
Meersch M, Weiss R, Gerss J, Albert F, Gruber J, Kellum JA, et al. Predicting the development of renal replacement therapy indications by combining the furosemide stress test and chemokine (C-C Motif) ligand 14 in a cohort of postsurgical patients. Crit Care Med. 2023;51(8):1033–42.
pubmed: 36988335
pmcid: 10335738
doi: 10.1097/CCM.0000000000005849
Hoste EAJ, Kellum JA, Selby NM, Zarbock A, Palevsky PM, Bagshaw SM, et al. Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol. 2018;14(10):607–25.
pubmed: 30135570
doi: 10.1038/s41581-018-0052-0
Peerapornratana S, Fiorentino M, Priyanka P, Murugan R, Kellum JA. Recovery after AKI: effects on outcomes over 15 years. J Crit Care. 2023;76: 154280.
pubmed: 36848723
pmcid: 10238673
doi: 10.1016/j.jcrc.2023.154280
Qian BS, Jia HM, Weng YB, Li XC, Chen CD, Guo FX, et al. Analysis of urinary C-C motif chemokine ligand 14 (CCL14) and first-generation urinary biomarkers for predicting renal recovery from acute kidney injury: a prospective exploratory study. J Intensive Care. 2023;11(1):11.
pubmed: 36941674
pmcid: 10026399
doi: 10.1186/s40560-023-00659-2
Koyner JL, Shaw AD, Chawla LS, Hoste EA, Bihorac A, Kashani K, et al. Tissue inhibitor metalloproteinase-2 (TIMP-2)⋅IGF-binding protein-7 (IGFBP7) levels are associated with adverse long-term outcomes in patients with AKI. J Am Soc Nephrol. 2015;26(7):1747–54.
pubmed: 25535301
doi: 10.1681/ASN.2014060556
Dépret F, Hollinger A, Cariou A, Deye N, Vieillard-Baron A, Fournier MC, et al. Incidence and outcome of subclinical acute kidney injury using penkid in critically ill patients. Am J Respir Crit Care Med. 2020;202(6):822–9.
pubmed: 32516543
doi: 10.1164/rccm.201910-1950OC
Legrand M, Hollinger A, Vieillard-Baron A, Dépret F, Cariou A, Deye N, et al. One-year prognosis of kidney injury at discharge from the ICU: a multicenter observational study. Crit Care Med. 2019;47(12):e953–61.
pubmed: 31567524
doi: 10.1097/CCM.0000000000004010
Coca SG, Garg AX, Thiessen-Philbrook H, Koyner JL, Patel UD, Krumholz HM, et al. Urinary biomarkers of AKI and mortality 3 years after cardiac surgery. J Am Soc Nephrol. 2014;25(5):1063–71.
pubmed: 24357673
doi: 10.1681/ASN.2013070742
Stanski NL, Rodrigues CE, Strader M, Murray PT, Endre ZH, Bagshaw SM. Precision management of acute kidney injury in the intensive care unit: current state of the art. Intensive Care Med. 2023;49(9):1049–61.
pubmed: 37552332
doi: 10.1007/s00134-023-07171-z
Gordon AC, Alipanah-Lechner N, Bos LD, Dianti J, Diaz JV, Finfer S, et al. From ICU syndromes to ICU subphenotypes: consensus report and recommendations for developing precision medicine in ICU. Am J Respir Crit Care Med. 2024. https://doi.org/10.1164/rccm.202311-2086SO .
doi: 10.1164/rccm.202311-2086SO
pubmed: 38687499
pmcid: 11273306
Legrand M, Bagshaw SM, Bhatraju PK, Bihorac A, Caniglia E, Khanna AK, et al. Sepsis-associated acute kidney injury: recent advances in enrichment strategies, sub-phenotyping and clinical trials. Crit Care. 2024;28(1):92.
pubmed: 38515121
pmcid: 10958912
doi: 10.1186/s13054-024-04877-4
Bhatraju PK, Zelnick LR, Herting J, Katz R, Mikacenic C, Kosamo S, et al. Identification of acute kidney injury subphenotypes with differing molecular signatures and responses to vasopressin therapy. Am J Respir Crit Care Med. 2019;199(7):863–72.
pubmed: 30334632
pmcid: 6444649
doi: 10.1164/rccm.201807-1346OC
Ostermann M, Zarbock A, Goldstein S, Kashani K, Macedo E, Murugan R, et al. Recommendations on acute kidney injury biomarkers from the acute disease quality initiative consensus conference: a consensus statement. JAMA Netw Open. 2020;3(10): e2019209.
pubmed: 33021646
doi: 10.1001/jamanetworkopen.2020.19209
Schanz M, Wasser C, Allgaeuer S, Schricker S, Dippon J, Alscher MD, et al. Urinary [TIMP-2]·[IGFBP7]-guided randomized controlled intervention trial to prevent acute kidney injury in the emergency department. Nephrol Dial Transplant. 2019;34(11):1902–9.
pubmed: 29961888
doi: 10.1093/ndt/gfy186
von Groote T, Meersch M, Romagnoli S, Ostermann M, Ripollés-Melchor J, Schneider AG, et al. Biomarker-guided intervention to prevent acute kidney injury after major surgery (BigpAK-2 trial): study protocol for an international, prospective, randomised controlled multicentre trial. BMJ Open. 2023;13(3): e070240.
doi: 10.1136/bmjopen-2022-070240
Gómez H, Zarbock A, Pastores SM, Frendl G, Bercker S, Asfar P, et al. Feasibility assessment of a biomarker-guided kidney-sparing sepsis bundle: the limiting acute kidney injury progression in sepsis trial. Crit Care Explor. 2023;5(8): e0961.
pubmed: 37614799
pmcid: 10443738
doi: 10.1097/CCE.0000000000000961
Kane-Gill SL, Peerapornratana S, Wong A, Murugan R, Groetzinger LM, Kim C, et al. Use of tissue inhibitor of metalloproteinase 2 and insulin-like growth factor binding protein 7 [TIMP2]•[IGFBP7] as an AKI risk screening tool to manage patients in the real-world setting. J Crit Care. 2020;57:97–101.
pubmed: 32086072
doi: 10.1016/j.jcrc.2020.02.002
Gaspari F, Cravedi P, Mandalà M, Perico N, de Leon FR, Stucchi N, et al. Predicting cisplatin-induced acute kidney injury by urinary neutrophil gelatinase-associated lipocalin excretion: a pilot prospective case-control study. Nephron Clin Pract. 2010;115(2):c154–60.
pubmed: 20407275
doi: 10.1159/000312879
Rocha PN, Macedo MN, Kobayashi CD, Moreno L, Guimarães LH, Machado PR, et al. Role of urine neutrophil gelatinase-associated lipocalin in the early diagnosis of amphotericin B-induced acute kidney injury. Antimicrob Agents Chemother. 2015;59(11):6913–21.
pubmed: 26303800
pmcid: 4604365
doi: 10.1128/AAC.01079-15
Karimzadeh I, Barreto EF, Kellum JA, Awdishu L, Murray PT, Ostermann M, et al. Moving toward a contemporary classification of drug-induced kidney disease. Crit Care. 2023;27(1):435.
pubmed: 37946280
pmcid: 10633929
doi: 10.1186/s13054-023-04720-2
Dieterle F, Sistare F, Goodsaid F, Papaluca M, Ozer JS, Webb CP, et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and predictive safety testing consortium. Nat Biotechnol. 2010;28(5):455–62.
pubmed: 20458315
doi: 10.1038/nbt.1625
Birkelo BC, Koyner JL, Ostermann M, Bhatraju PK. The road to precision medicine for acute kidney injury. Crit Care Med. 2024;52(7):1127–37.
pubmed: 38869385
pmcid: 11250999
doi: 10.1097/CCM.0000000000006328
Koyner JL, Arndt C, Martinez B, de Irujo J, Coelho S, Garcia-Montesinos de la Peña M, di Girolamo L, et al. Assessing the role of Chemokine (C-C motif) ligand 14 in AKI: a European consensus meeting. Ren Fail. 2024;46(1):2345747.
pubmed: 38666354
pmcid: 11057457
doi: 10.1080/0886022X.2024.2345747
Ostermann M, Wu V, Sokolov D, Lumlertgul N. Definitions of acute renal dysfunction: an evolving clinical and biomarker paradigm. Curr Opin Crit Care. 2021;27(6):553–9.
pubmed: 34535002
doi: 10.1097/MCC.0000000000000886
Echeverri J, Martins R, Harenski K, Kampf JP, McPherson P, Textoris J, et al. Exploring the cost-utility of a biomarker predicting persistent severe acute kidney injury: the case of c-c motif chemokine ligand 14 (CCL14). Clinicoecon Outcomes Res. 2024;16:1–12.
pubmed: 38235419
pmcid: 10790637
doi: 10.2147/CEOR.S434971